Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R. Ali A, et al. Among authors: puissant a. Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. Leukemia. 2018. PMID: 29535430 No abstract available.
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.
Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J. Willems L, et al. Among authors: puissant a. Leukemia. 2012 Jun;26(6):1195-202. doi: 10.1038/leu.2011.339. Epub 2011 Dec 6. Leukemia. 2012. PMID: 22143671
BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T, Robert G, Mounier N, Karsenti JM, Dufies M, Puissant A, Jacquel A, Renneville A, Preudhomme C, Cassuto JP, Raynaud S, Luciano F, Auberger P. Cluzeau T, et al. Among authors: puissant a. Oncotarget. 2012 Apr;3(4):490-501. doi: 10.18632/oncotarget.481. Oncotarget. 2012. PMID: 22577154 Free PMC article.
LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G. Dubois A, et al. Among authors: puissant a. Leukemia. 2019 Jun;33(6):1501-1513. doi: 10.1038/s41375-018-0336-1. Epub 2019 Jan 3. Leukemia. 2019. Retraction in: Leukemia. 2020 Sep;34(9):2544. doi: 10.1038/s41375-020-0969-8. PMID: 30607021 Retracted.
BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
Massé A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, Ali A, Alberdi A, Berrou J, Passet M, Hernandez L, Quentin S, Gardin C, Raffoux E, Adès L, Braun T, Soulier J, Clappier E, Dombret H, Puissant A, Itzykson R. Massé A, et al. Among authors: puissant a. Leuk Res. 2019 Dec;87:106269. doi: 10.1016/j.leukres.2019.106269. Epub 2019 Nov 7. Leuk Res. 2019. PMID: 31751766
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.
Lin KH, Rutter JC, Xie A, Pardieu B, Winn ET, Bello RD, Forget A, Itzykson R, Ahn YR, Dai Z, Sobhan RT, Anderson GR, Singleton KR, Decker AE, Winter PS, Locasale JW, Crawford L, Puissant A, Wood KC. Lin KH, et al. Among authors: puissant a. Nat Genet. 2020 Apr;52(4):408-417. doi: 10.1038/s41588-020-0590-9. Epub 2020 Mar 16. Nat Genet. 2020. PMID: 32203462 Free PMC article.
CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia.
Schmoellerl J, Barbosa IAM, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson R, Moriggl R, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F. Schmoellerl J, et al. Among authors: puissant a. Blood. 2020 Jul 23;136(4):387-400. doi: 10.1182/blood.2019003267. Blood. 2020. PMID: 32344427 Free PMC article.
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.
Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debré I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, Roti G, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant A. Su A, et al. Among authors: puissant a. Cancer Discov. 2020 Dec;10(12):1894-1911. doi: 10.1158/2159-8290.CD-19-0970. Epub 2020 Aug 21. Cancer Discov. 2020. PMID: 32826232 Free PMC article.
303 results